TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Dose Limiting Toxicities (DLTs) occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of small for gestational age infants screened
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in small intestinal permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Surgeon Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain Score at 3 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to administer an eye drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post episiotomy pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary Artery Calcium Score Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intra-class Correlation Coefficient of Tracer Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Numeric Rating Scale - TEST RETEST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Get up and Go - TEST RETEST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The 30 Seconds Sit to Stand - TEST RETEST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The 20-meter Walk - TEST RETEST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TSH (thyroid-stimulating hormone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in the LDL cholesterol/ HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Onset of an eating disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Dim Light Melatonin Onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale Global Tic Severity Scale (YGTSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness of immunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in child emotional and behavioral problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Woodcock Reading Mastery Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of implants ideally placed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Measurement of Radiation Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in tidal volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Renal and blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence Rate of Stroke and Systemic Embolism
Endpoint domain: Mortality/survival
Primary endpoint: Radiological analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total sleep time (TST) average on weeknights
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Average bedtime on weeknights
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Morning Eveningness preference
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Satisfaction to the community activities
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Depression Subscale score of the Hospital Anxiety and Depression Scale (HADS-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Anxiety Subscale score of the Hospital Anxiety and Depression Scale (HADS-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Survival without needs of ventilator utilization at day 14
Endpoint domain: Mortality/survival
Primary endpoint: WHO progression scale ≤ 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of successful tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Parent's satisfaction with IV placement procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of Clinical Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of return to social engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Glycaemic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement and/or stabilization of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Completed Four Cycles of the Carboplatin/Docetaxel Regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of spontaneous falls
Endpoint domain: Adverse events/effects
Primary endpoint: Time-to-progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Drug Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the (first) moment plasma concentration-time curve (AUMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement Agreement between IOL Master Software Versions 1.70 and 1.50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement Agreement between IOLMaster Software Version 1.70 and Pentacam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability and Reproducibility of IOLMaster 700 Software Version 700 Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of conversion to an open circuit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Performance time of block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of males circumcised
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Joint Position Sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Body Surface Area of Erythema With Pustules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete PMTCT retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: hemoglobin value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of activation of inflammasomes in monocytes and polymorphonuclear neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: outcome of primary PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ocular pain from Glia OSD Symptoms Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Graft Patency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Primary-Assisted Graft Patency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ambulance recruitment rate per million of population
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of olaparib
Endpoint domain: Adverse events/effects
Primary endpoint: Breathing Comfort & Discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Positive and Negative Symptom Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with PegPen preparation and injection easiness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GSV Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of Progression-free Patients at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Diabetic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in quality of life in patients after the implementation of ML
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects With Confirmed Herpes Zoster Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Sexual Desire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Glycated Hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of FSH receptor polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Retinal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Back Pain Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VAS Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Revised Oswestry Pain Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Adverse Event of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Remodelling of heart function and structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis of dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnosis of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pancreatic ductal adenocarcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and specificity of serum CA 19-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC(0-24)) for Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum drug concentration (Cmax) in plasma for Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC(0-24)) for rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum drug concentration (Cmax) in plasma for rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric rating scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum Sodium Concentration Corrected to at Least 135 mEq/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venous thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Behavior Rating Inventory of Executive Function (BRIEF)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Teamwork assessed by Simulation about Shortness of Breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Teamwork assessed by Simulation about Negotiation with Angry Patient
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression symptom score on PHQ-9 at post-intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression symptom score on PHQ-9 at 6-month follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with ≥ grade 3 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pepsin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: variability in enhancement levels for DCIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Optical spectroscopic measurements of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance from marked points to stimulated point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infants' immunoprophylaxis failure
Endpoint domain: Adverse events/effects
Primary endpoint: Return to Recreational and Fitness Activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Patient Participants Who Experience Illness Relapse
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline to Endline in Disability (WHODAS 2.0)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline to Endline in Quality of Life (WHOQOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient volume status assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients refusing examination
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Diurnal cortisol variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Patients Continent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort Throughout the Day
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ADAS-cog/11 score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes of blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of C peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surgical site infection on post-op day 30
Endpoint domain: Adverse events/effects
Primary endpoint: CVL scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Momentary positive and negative emotion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in hematology and chemistry laboratory values from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SUVmax (Maximal Standardized Uptake Value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Emergence of Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: blood level of regulatory T cells (Treg, CD4+CD25HighFoxp3+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of inhibiting LT proliferation inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiac output measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variation of interleukin 1 plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Variation of interleukin 6 plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Variation of protein C reactive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 1 year incidence of target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average Analyte Concentration at Steady State (Cavg,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Observed Analyte Concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with methylated genes in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to chemotherapy (CR or PR radiologic response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Experiencing Dose-limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Six-month Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of hospitals that test for MIC creep to vancomycin
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hemoglobin A1c (HbA1c) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognitive Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional outcome day 7 post-operation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: quantitative measure of atrial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient overall response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Changes in Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Management Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Estimate of Functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in IPV assessments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of secondary aggravation
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response or disease stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma Total Homocysteine Concentration (tHcy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemical Response to Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation Attenuation in Percentage (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Radiation Exposure Outside of Cap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: overt diabetic nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: peripheral diabetic neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change from baseline Hb-A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number and site of suspicious lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response rate of very good partial response (VGPR) or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Histologic Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measure of Processes of Care (MPOC-20)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Changes in gene expression patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Vaccine Serogroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse Event Evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Female Sexual Function Index (FSFI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and tolerability of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Restorative sleep score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change of spinal cord function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Flanks fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved referrals to physicians
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Erythroid response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modified Observers Assessment of Alertness (MOAAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes